Drugs / Octavalent HPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00851643 | Apr 2006 → Dec 2007 | anogenital human papillomavirus infection, cervical cancer, vaginal cancer, vulva cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octavalent HPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00851643 ↗ |
| Modality | Vaccine | “Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine” NCT00851643 ↗ |
| Route | Intramuscular | “0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6” NCT00851643 ↗ |